The Immune Landscape of CancerVésteinn Thórsson, Robert A. Holt, David L. Gibbs et al.|Immunity|2018Cited by 6.2k
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironmentsKevin C. Barry, Matthew F. Krummel, Joy Hsu et al.|Nature Medicine|2018Cited by 1k
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Laura J. Esserman, Christina Yau et al.|Cancer Cell|2021Cited by 330
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysisFrançois‐Clément Bidard, Paul Cottu, Patrice Viens et al.|JNCI Journal of the National Cancer Institute|2018Cited by 282
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trialAmy S. Clark, Laura J. Esserman, Christina Yau et al.|Nature Communications|2021Cited by 73